Form 4: Theravance Biopharma Executive Acquires 37,500 Shares
SEC Form 4 Filing
Rhonda Farnum, SVP at Theravance Biopharma, acquired 37,500 ordinary shares on April 2, 2024.
Summary
- On April 2, 2024, Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, acquired 37,500 ordinary shares.
- The shares were acquired at a price of $0.
- Following the transaction, Farnum directly owns 349,233 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an executive's stock acquisition. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.
Positives
- An executive's increased stake in the company may signal confidence in its future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders of a company (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions and can be used by investors to gauge sentiment about the company's prospects.
Stakeholder Impact
- The transaction could influence investor perception of the company.
Key Dates
| Date | Description |
|---|---|
| 04/02/2024 | Date of transaction: Rhonda Farnum acquired 37,500 ordinary shares. |
| 04/04/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.